Trial Profile

A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Trastuzumab
Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms KEYNOTE-014; PANACEA

Most Recent Events

11 Feb 2019 Results (Data cut-off: Aug 7, 2017) published in the Lancet Oncology
27 Sep 2018 Status changed from active, no longer recruiting to completed.
27 Jun 2018 This trial has been completed in Austria (End date: 2018-01-31), according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com